Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of danicopan add-on to ravulizumab in previously treated PNH
MOH_2023-07-05_012796Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events and Serious treatment-emergent adverse events. Started Jun 2023; status: recruiting.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on MOH_2023-07-05_012796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-05_012796.